2MePI, also known as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, is a serotonin receptor modulator of the pyridoindole (γ-carboline) family. It is the pyridoindole homologue of the ibogalog (azepinoindole) ibogaminalog (DM-506).
The drug acts as a weak partial agonist or functional competitive antagonist of the serotonin 5-HT2A receptor, with an affinity (Ki) of 95nM, an () of 533nM (32%), an apparent of 3,100 to 18,000nM, and a KB of 89 to 228nM. Compared to ibogaminalog, 2MePi had 5-fold lower affinity, 59-fold lower activational potency, and less than half the activational efficacy at the serotonin 5-HT2A receptor. Results were analogous for 8MeO-2MePI against ibogainalog (8MeO-2MePI's ibogalog homologue). These findings indicate that ibogalogs are the more optimal structural scaffold for serotonin 5-HT2A receptor agonism.
2MePI was first described in the scientific literature by Matthias Liechti and colleagues in 2026.
See also Substituted γ-carboline Pyridopyrroloquinoxaline § Related compounds Tiflucarbine
References